Buy Ampakines · Best Pick

The ampakine market is currently split between high-level pharmaceutical development and high-cost research chemical suppliers.

: Previously popular nootropic vendors that occasionally carried ampakine-related derivatives have faced significant regulatory pressure; notably, Nootropics Depot pleaded guilty in 2024 to distributing unapproved drugs, effectively ending major domestic retail availability for these substances. Key Compounds in Development (2024–2026) buy ampakines

: RespireRx Pharmaceuticals currently leads development for compounds like CX1739 and CX717, primarily targeting ADHD and opioid-induced respiratory depression. The ampakine market is currently split between high-level

If you are tracking these for potential future availability, the following are the primary "active" candidates in the clinical pipeline: Preclinical Pharmacology of the Low-Impact Ampakine CX717 If you are tracking these for potential future

: Certain compounds like Sunifiram (an ampakine-like modulator) are listed by specialized scientific suppliers such as Biosynth , but these are strictly for laboratory research and are priced at roughly $900 per 5g.

Current market intelligence (as of April 2026) indicates that through standard retail or pharmaceutical channels, as no compounds in this class have received FDA approval . While they remain highly active in clinical research for ADHD and spinal cord injuries, they are largely confined to experimental and institutional settings. Current Availability and Market Status